Biotech Horizons, Near and Far

JP Morgan's Franklin Berger sees a correction in valuations soon. Then powerful appreciation over the next several years

The strides in genomics and the focus on proteins indicate a period of increased growth and development in the biotech sector. But these stocks, along with the rest of the market, will probably make little progress in the next few months, according to Franklin M. Berger, vice-president and senior biotechnology analyst for JP Morgan Securities.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.